Endo reaches resolution with DOJ regarding legacy marketing of Opana ER
EHSI agreed to plead guilty to a single strict liability misdemeanor misbranding violation of the Federal Food, Drug, and Cosmetic Act related to certain Opana ER marketing occurring between April 2012 and May 2013.